PHOSPHOINOSITIDE 3-KINASE ASSAYS IN CANCER DIAGNOSIS

Information

  • Research Project
  • 6335432
  • ApplicationId
    6335432
  • Core Project Number
    R43CA081835
  • Full Project Number
    5R43CA081835-02
  • Serial Number
    81835
  • FOA Number
    PAR-98-066
  • Sub Project Id
  • Project Start Date
    8/1/1999 - 25 years ago
  • Project End Date
    7/31/2001 - 23 years ago
  • Program Officer Name
    SRIVASTAVA, SUDHIR
  • Budget Start Date
    9/8/2000 - 24 years ago
  • Budget End Date
    7/31/2001 - 23 years ago
  • Fiscal Year
    2000
  • Support Year
    2
  • Suffix
  • Award Notice Date
    9/8/2000 - 24 years ago

PHOSPHOINOSITIDE 3-KINASE ASSAYS IN CANCER DIAGNOSIS

Phosphoinositide polyphosphates (PtdInsPns), biosynthesized by the interplay of kinases and phosphatases, are key signaling molecules in cellular communication. The lipid kinase, phosphatidylinositol 3-kinase (PI 3-K) has been identified in the control of diverse cellular processes such as proliferation and differentiation, tumorigenesis, and apoptosis. The use of PI 3-K and its lipid products, PtdIns(3,4,5)P2 and PtdIns(4,5)P2, as potential tumor markers in the early detection of cancer would be substantially enhanced with the development of rapid 96-well format assay kits for lipid kinase activity. Vast clinical isolets from epithelial cancer origin could be screened in such a high throughput assay format. Echelon Research Laboratories (ERL) has developed syntheses of commericalized PtdInsPns. In our second tier strategy, these PtdInsPns as well as licensed monoclonal antibodies against phosphoinositides will be employed to prepare assay plates containing a specific immobilized substrate using Flashplate(TM) and ELISA technologies, respectively. We will focus on the use of PtdIns(4,5)P2 as a substrate for PI 3-K to develop and optimize assay kits against benchmark techniques. Subsequent screening of various types of epithelial cancer isolets will be pursued to determine the significance of PI 3-K and its lipid products as a reliable diagnostic tool in cancer research. PROPOSED COMMERCIAL APPLICATIONS: The research would lead to production of 96-well assay kits for rapid testing of PI 3-K as a potential tumor marker in clinical isolets taken from various origins of epithelial cancer cells. Systematic screening of multiple cancerous cell extracts will allow rapid detection of tissue- or physiology- specific activities. Screening of libraries of compounds will allow detection of potential isozyme-specific inhibitors as therapeutic leads. Major pharmaceutical companies, numerous biotech start-ups, and hundreds of academic laboratories would employ such kits for basic and applied research.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R43
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    104500
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:104500\
  • Funding Mechanism
  • Study Section
    ZCA1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    ECHELON BIOSCIENCES, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    SALT LAKE CITY
  • Organization State
    UT
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    84108
  • Organization District
    UNITED STATES